阿昔替尼改善了一名 12 岁男孩的杜匹单抗耐药重度特应性皮炎合并轻度脱发：随访 1 年的病例报告

IF 3.7 3区医学 Q2 ALLERGY

Journal of Asthma and Allergy Pub Date : 2024-04-02 DOI:10.2147/jaa.s458684

Xiaohan Liu, Biao Song, Hongzhong Jin

{"title":"阿昔替尼改善了一名 12 岁男孩的杜匹单抗耐药重度特应性皮炎合并轻度脱发：随访 1 年的病例报告","authors":"Xiaohan Liu, Biao Song, Hongzhong Jin","doi":"10.2147/jaa.s458684","DOIUrl":null,"url":null,"abstract":"Abstract: Atopic dermatitis (AD) may sometimes be comorbid with alopecia areata (AA). However, traditional treatments for AA show limited efficacy. New treatment options, such as dupilumab and Janus kinase inhibitors, have proven efficacy in addressing both AD and AA. This article highlights the challenging case of a 12-year-old boy experiencing severe refractory AD and comorbid AA treated with oral abrocitinib after dupilumab failure with 1-year follow-up. After 3 months of treatment, his skin manifestations improved and the hair completely regenerated. No adverse reactions were observed during the 1-year follow-up period. This case provides evidence of the efficacy and safety of using abrocitinib to treat pediatric patients with both AD and AA. Keywords: atopic dermatitis, alopecia areata, Janus kinase inhibitors, dupilumab ","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"49 1","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up\",\"authors\":\"Xiaohan Liu, Biao Song, Hongzhong Jin\",\"doi\":\"10.2147/jaa.s458684\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract: Atopic dermatitis (AD) may sometimes be comorbid with alopecia areata (AA). However, traditional treatments for AA show limited efficacy. New treatment options, such as dupilumab and Janus kinase inhibitors, have proven efficacy in addressing both AD and AA. This article highlights the challenging case of a 12-year-old boy experiencing severe refractory AD and comorbid AA treated with oral abrocitinib after dupilumab failure with 1-year follow-up. After 3 months of treatment, his skin manifestations improved and the hair completely regenerated. No adverse reactions were observed during the 1-year follow-up period. This case provides evidence of the efficacy and safety of using abrocitinib to treat pediatric patients with both AD and AA. Keywords: atopic dermatitis, alopecia areata, Janus kinase inhibitors, dupilumab \",\"PeriodicalId\":15079,\"journal\":{\"name\":\"Journal of Asthma and Allergy\",\"volume\":\"49 1\",\"pages\":\"\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-04-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Asthma and Allergy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/jaa.s458684\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Asthma and Allergy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/jaa.s458684","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

摘要

摘要：特应性皮炎（AD）有时会合并斑秃（AA）。然而，传统的脱发治疗方法疗效有限。新的治疗方案，如杜比鲁单抗和Janus激酶抑制剂，已被证明对治疗AD和AA均有疗效。本文重点介绍了一个具有挑战性的病例：一名 12 岁男孩患有严重难治性 AD 并合并 AA，在杜匹鲁单抗治疗失败后接受了口服阿罗西替尼治疗，随访 1 年。治疗 3 个月后，他的皮肤表现有所改善，头发完全再生。在 1 年的随访期间，未发现任何不良反应。本病例为使用阿昔替尼治疗同时患有特应性皮炎和斑秃的儿童患者的有效性和安全性提供了证据。关键词：特应性皮炎、斑秃、Janus激酶抑制剂、杜鲁单抗

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up

Abstract: Atopic dermatitis (AD) may sometimes be comorbid with alopecia areata (AA). However, traditional treatments for AA show limited efficacy. New treatment options, such as dupilumab and Janus kinase inhibitors, have proven efficacy in addressing both AD and AA. This article highlights the challenging case of a 12-year-old boy experiencing severe refractory AD and comorbid AA treated with oral abrocitinib after dupilumab failure with 1-year follow-up. After 3 months of treatment, his skin manifestations improved and the hair completely regenerated. No adverse reactions were observed during the 1-year follow-up period. This case provides evidence of the efficacy and safety of using abrocitinib to treat pediatric patients with both AD and AA.

Keywords: atopic dermatitis, alopecia areata, Janus kinase inhibitors, dupilumab

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Asthma and Allergy Medicine-Immunology and Allergy

CiteScore

5.30

自引率

6.20%

发文量

185

审稿时长

16 weeks

期刊介绍： An international, peer-reviewed journal publishing original research, reports, editorials and commentaries on the following topics: Asthma; Pulmonary physiology; Asthma related clinical health; Clinical immunology and the immunological basis of disease; Pharmacological interventions and new therapies. Although the main focus of the journal will be to publish research and clinical results in humans, preclinical, animal and in vitro studies will be published where they shed light on disease processes and potential new therapies.